Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Your search for process/pmg6 returned no results
Showing 2821 to 2835 of 2854 results for process

  1. Cutting-edge robotic surgery gets green light as 11 systems are recommended

    Eleven cutting-edge robotic surgery systems have been approved for use, potentially transforming care for thousands of NHS patients undergoing soft tissue and orthopaedic procedures.

  2. Starting with the end in mind - the Innovative Licensing and Access Pathway

    The Innovative Licensing and Access Pathway (ILAP) will smooth the process by which innovative new medicines are developed, speeding their progression from clinical trial through to the NHS, bringing significant benefits to patients.

  3. HST routing criteria: encouraging innovation in the treatment of ultra-rare diseases

    Our chief medical officer, Professor Jonathan Benger, explains the crucial role the HST programme plays in encouraging innovation in the treatment of ultra-rare diseases. He also highlights why effective routing is essential to getting the best care to patients across the NHS.

  4. Introducing a new way of prioritising our guidance topics

    NICE's deputy chief executive, Jonathan Benger, talks about our new approach to prioritisation.

  5. NICE collaboration on streamlined licensing and patient access process for new medicines

    Companies can now submit medicines for the new Innovative Licensing and Access Pathway (ILAP) following close collaboration between the NICE, drug regulators, the NHS and equivalent organisations in Scotland.

  6. How NICE manages the potential conflicts of interests of patient experts

    People with lived experience provide valuable insight into the impact of NICE’s’ guidance and advice.

  7. How my experience as a patient helped shape NICE guidelines for colorectal cancer

    Following my surgery and treatment for colorectal cancer in 2014, I wanted to contribute to research in the cancer field and hopefully improve things for patients in the future.

  8. A 'safe space' for addressing complex health technology assessment challenges

    Nick Crabb discusses how we’re developing a collaborative space for research and development, to help us create new methods and processes for health technology assessment.

  9. World's first gene editing therapy for blood disorder to be available to hundreds of patients in England

    Patients in England with severe beta-thalassaemia will be amongst the first in Europe to benefit from one-time gene therapy exagamglogene autotemcel.

  10. NICE to become single point of access for Covid-19 guidance and advice

    NICE announced that it is to host a new, single point of advice on caring for people with Covid-19 and the management of Covid-19 in a variety of clinical settings.

  11. NICE announces start of review of nusinersen Managed Access Agreement

    NICE has today (29 October 2020) announced that it has begun the process to review data collected as part of the Managed Access Agreement (MAA) for nusinersen.

  12. NICE collaborates with international partner agencies to streamline the confidential marking process

    NICE, the Canadian Agency for Drugs and Technologies in Health and the US’s Institute for Clinical and Economic Review changes the way information about health technologies is handled to streamline processes and increase transparency.

  13. NICE's flexibility in evaluation of new health tech and fairer patient access

    Changes to the way medicines and other health technologies are evaluated by NICE for use in the NHS were approved by its Board.

  14. Celebrating the people who support NICE: International Volunteer Day

    Applauding the members of the public who donate their valuable experience and insight to NICE.

  15. NICE sets out further details on menopause guideline update

    NICE has outlined what aspects of menopause care will be updated in upcoming guidance, including areas where more research is needed.